Mauna Kea Technologies manufactures Cellvizio Lab, confocal probe based imaging system, providing cellular-level images with minimal invasiveness for longitudinal studies.
Discover
Related topics
Advances in Leukemia research using shear flow and Bioflux system
Feb 3, 2023
Leukemia is a rare cancer with many subtypes. The production of abnormal leukocytes create disruptions in the immune...
Webinar: Dose Reduction and Image Enhancement in Preclinical Mouse Imaging using Deep Learning
Jan 31, 2023
In this webinar, ir. Florence Muller (Ghent University - University of Pennsylvania) is presenting two recent studies...
Advance your Spatial Biology, customize your panel design with RareCyte Orion reagents
Jan 23, 2023
Orion system, the highly multiplexed fluorescent imaging system, in combination with dedicated reagents, empower...
Extensive assessment of Cytokine production on the NovoCyte Advanteon flow cytometer
Jan 13, 2023
Cytokines are small molecules essential for immune cell response to activation by pathogens, autoimmunity, or...
New installation of Cytek Aurora in Slovenia
Jan 11, 2023
2nd spectral flowcytometer Aurora from Cytek was installed at National Institute of Biology in Slovenia
Microfluidic cell sorter sample preparation for genomic assays
Dec 16, 2022
Single-cell RNA-Sequencing has led to many novel discoveries such as the detection of rare cell populations, microbial...
Dec 1, 2022
Cytek Cloud is the new digital ecosystem that supports full spectrum flow cytometry research from panel design to data...
See More, Sort More with Cytek Full Spectrum Systems
Nov 28, 2022
Still wondering whether to join the shift to full spectrum cytometry? Easily transfer assays from your Cytek Northern...
Demonstrate the value of RareCyte Orion system via web-based Minerva viewer
Nov 25, 2022
The HTA CRC Atlas X dataset contains images and other data being used for construction of an atlas of human colorectal...
Practical aspects of an imaging study: live in vivo scanning
Nov 11, 2022
In this webinar, MOLECUBES will present a live in vivo demonstration, showing the entire workflow from animal...
Mar 29, 2018
The heterogeneity of pancreatic ductal adenocarcinoma (PDAC) suggests that successful treatment might rely on simultaneous targeting of multiple genes, which can be achieved by RNA interference-based therapeutic strategies. Hadas Gibori (Department of Physiology and Pharmacology, Sackler Faculty of Medicine, Tel Aviv University) and his team show here a potent combination of microRNA and siRNA delivered by an efficient nanocarrier to PDAC tumors.
Using proteomic-microRNA profiles and survival data of PDAC patients from TCGA, they found a novel signature for prolonged survival. Accordingly, they used a microRNA-mimic to increase miR-34a together with siRNA to silence PLK1 oncogene. For in vivo dual-targeting of this combination, they developed a biodegradable amphiphilic polyglutamate amine polymeric nanocarrier (APA). APA-miRNA–siRNA polyplexes systemically administered to orthotopically inoculated PDAC-bearing mice showed no toxicity and accumulated at the tumor, resulting in an enhanced antitumor effect due to inhibition of MYC oncogene, a common target of both miR-34a and PLK1. Taken together, their findings warrant this unique combined polyplex’s potential as a novel nanotherapeutic for PDAC.
Brand profile
Mauna Kea Technologies manufactures Cellvizio Lab, confocal probe based imaging system, providing cellular-level images with minimal invasiveness for longitudinal studies.
More info at:
www.cellviziolab.com/